Site icon pharmaceutical daily

Leading Liver Disease Researchers Present at EASL International Liver Congress™ 2019, Demonstrate Echosens FibroScan® as Optimal Screening Tool for Liver Disease

WALTHAM, Mass. & PARIS–(BUSINESS WIRE)–Echosens,
an innovative high-technology company offering the FibroScan®
family of products, today announces that distinguished researchers,
notably Stephen Harrison, M.D., visiting professor of Hepatology,
Radcliffe Department of Medicine, University of Oxford, and Jerome
Boursier, M.D., Ph.D., professor of Medicine, Hepato-Gastroenterology
Department of Angers University Hospital, and head of HIFIH laboratory,
Angers University in France, will present studies supporting the value
of FibroScan at EASL’s
International Liver Congress™
, in Vienna, Austria, April 10-14,
2019. FibroScan will be included in over 163 abstracts including 18 oral
presentations that will evaluate utilization of the non-invasive
FibroScan® tool across a variety of liver disease etiologies and
practice settings. An area of focus is the use of VCTE™ and CAP™ to
efficiently screen and identify patients with active fibrotic
nonalcoholic steatohepatitis (NASH); to cost-effectively use the
technology in the physician’s office; and to significantly improve
detection of fibrosis in non-alcoholic fatty liver disease (NAFLD)
patients.

Dr. Harrison explains, “A FibroScan-based score combining liver
stiffness, controlled attenuation parameter (CAP™) and aspartate
aminotransferase (AST) can efficiently screen for presence of at-risk
fibrotic NASH. This non-invasive test is documented to quickly and cost
effectively provide a quantitative assessment of liver stiffness and fat
and can accurately identify patients eligible for potential
pharmacologic therapy.”

He says this meeting furthers the worldwide understanding of liver
research, enhances the clinical practice of liver disorders and educates
those interested in hepatology. He points to over 2,000 peer-reviewed
research publications which position FibroScan as the most widely
studied tool for point of care liver assessment.

During the Congress, Dr. Harrison will also present seminal work on the
prospective liver biopsy-based prevalence of NAFLD/NASH among a large
middle-aged population, utilizing FibroScan, LiverMultiscan and magnetic
resonance elastography (MRE). Additionally, he will present findings
related to predicting the severity of hepatic steatosis and fibrosis by
transient elastography and magnetic resonance imaging (MRI)-based
techniques in adult patients with suspected NAFLD.

Attendees will hear an oral presentation by Dr. Boursier on April 14,
2019, showing external validation in NAFLD cohorts of a FibroScan-based
score combining liver stiffness via VCTE™, CAP™ and AST to identify
patients with active NASH (NAS>=4) and significant fibrosis (F>=2). The
results of his study show that a simple score based on FibroScan LSM,
CAP and AST demonstrated good performance in all NAFLD cohorts.

“I want to emphasize that FibroScan could be used in specialty and
primary care settings to efficiently screen patients with active NASH
(NAS≥4) and significant fibrosis (F≥2) for drug trials, as well as to
identify patients eligible for treatment when the drugs currently
evaluated in clinical trials will become available on the market” says
Dr. Boursier.

Other presentations include:

About Echosens

Echosens, the developer of FibroScan®, is a world leader in non-invasive
medical devices dedicated to the assessment of liver disease. Echosens
offers a full range of point of care products and services supporting
physicians management of patients with chronic liver diseases. With a
wide-reaching international distribution network including France
(Paris), the United States (Waltham) and China (Shanghai, Shenzhen and
Beijing), Echosens has made FibroScan® available in over 80 countries. http://www2.echosens.com/AboutFibroScan.

Contacts

Media:
Mary Spardel
CPR Communications
mspardel@cpronline.com
201.641.1911
x 22

Exit mobile version